Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders

A significant number of patients with hematologic malignancies need a hematopoietic stem cell transplant (HSCT) to be cured. Only about 50% of these patients have a fully matched donor, the remaining patients will require an HSCT from a mismatched related or unrelated donor. Almost 60% of these mismatched donor HSCTs will result in graft-versus-host disease (GvHD), which can cause significant morbidity and increased non-relapse mortality. GvHD is caused by the donor effector T cells present in the HSC graft that recognize and react against the mismatched patient's tissues.

Researchers and physicians at Lucile Packard Children's Hospital, Stanford are working to prevent GvHD after HSCT with a new clinical trial. The objective of this clinical program is to develop a cell therapy to prevent GvHD and induce graft tolerance in patients receiving mismatched unmanipulated donor HSCT. The cell therapy consists of a cell preparation from the same donor of the HSCT (T-allo10) containing T regulatory type 1 (Tr1) cells able to suppress allogenic (host-specific) responses, thus decreasing the incidence of GvHD.

This is the first trial of its kind in pediatric patients and is only available at Lucile Packard Children's Hospital, Stanford.

The purpose of this phase 1 study is to determine the safety and tolerability of a cell therapy, T-allo10, to prevent GvHD in patients receiving mismatched related or mismatched unrelated unmanipulated donor HSCT for hematologic malignancies.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Biological: T-allo10


Phase 1


Inclusion Criteria:

   1. Eligible diseases include:

   A. Acute Lymphoblastic Leukemia (B- or T-ALL)

      1. Complete Response (CR)1-ultra high risk features

         - Unfavorable cytogenetics

         - Hypodiploidy

         - Induction failure

         - Minimal Residual Disease (MRD) >1% after consolidation

      2. CR-2:

         - B-ALL: any relapse within 6 months

         - T- ALL

      3. CR-3-any

   B. Acute Myeloid Leukemia

      1. MRD >5% at day 22 induction 1

      2. MRD >0.1% after induction 2

      3. FMS-like tyrosine kinase (FLT) / Internal tandem duplication(ITD) and MRD >0.1%
      at day 29 induction 1

      4. Translocation (6:9), (8:6), (16:21), monosomy 7, monosomy 5, 5q

      5. M7 without Translocation (1:22)

      6. Therapy related or Secondary AML

      7. Refractory anemia with excess blasts (RAEB)2

   C. Myelodysplastic syndrome D. Mixed Phenotype Acute Leukemia MRD>1% after
   consolidation E. Non-Hodgkin's lymphoma (NHL) or Hodgkin's lymphoma (HL) beyond first

   2. Subjects 1 and 2 (in Cohort 1) will be ≥ 12 years' old

   3. Available mismatched related donor (mMRD) or mismatched unrelated donor (mMUD), Human
   leukocyte antigen (HLA) matched 8/10 or 9/10

   4. Lansky (age <16) or Karnofsky (age ≥16) performance status ≥80%

   5. Have adequate organ function defined as the following:

      - Serum Creatinine <1.5 X upper limit of normal (ULN) or 24-hour creatinine
      clearance >50 ml/min

      - Serum bilirubin ≤ 2 x ULN

      - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)

      ≤10 x ULN

      - Diffusion Capacity of the Lungs (DLCO) >60% predicted (in children, O2 saturation
      >92% on room air)

      - Left ventricular ejection fraction >45% (in children, shortening fraction >26%)

   6. Male and female subjects of child bearing potential must agree to use an effective
   method of birth control to avoid pregnancy throughout the transplant procedure, while
   on immunosuppression, and if the subject experiences any chronic GvHD.

Exclusion Criteria:

   1. Prior bone marrow or peripheral blood HSCT within the last 6 (six) months

   2. HLA-matched related or unrelated donor available

   3. Any active, uncontrolled infection at the time of treatment

   4. Pregnant or lactating females

   5. Any severe concurrent disease which, in the judgement of the investigator, would place
   the patient at increased risk during participation in the study

   6. Any subject with a history of significant renal, hepatic, pulmonary, or cardiac
   dysfunction or on treatment to support cardiac dysfunction

   7. HIV positive

   8. Non-cooperative behavior or non-compliance of the patient and/or of his/her family

   9. Received another investigational agent within 30 days of enrollment

10. Patients with Down's syndrome

Ages Eligible for Study

3 Years - 30 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Gopin Saini, MBBS, CCRC

New Trial Alerts

Receive email alerts when trials open to patients.